Clinical trials: Esophageal Ulcer
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD) treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven…
- Trial name
- NCT00251693
- Testing
- Dexlansoprazole MR, Lansoprazole
- Where
- 140 sites in United States, Australia and 13 more
- Volunteers
- 2,038 people
- Sponsor
- Takeda
GERD
Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use
The purpose of the study is to examine the impact of augmented, high-quality physician-coordinated care executed via an electronic health record (EHR)-based intervention on quality of care for gastroesophageal reflux disease…
- Trial name
- NCT00691171
- Volunteers
- 5,234 people
- Sponsor
- AstraZeneca
Reflux Esophagitis
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
This open label, non-interventional study is to compare the efficacy of Omepral® tablet and any other treatments excepting proton pump inhibitors (PPIs) for the treatment of various type of acid reflux related symptoms in…
- Trial name
- OMAREE (NCT00859287)
- Volunteers
- 10,703 people
- Sponsor
- AstraZeneca
Reflux Esophagitis, Gastric Ulcer
A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
This is an open label, parallel group, multi-centre, phase III study to assess the safety and efficacy of D961H in maintenance therapy following initial healing therapy in Japanese paediatric patients with reflux esophagitis, and…
- Conditions
- Reflux Esophagitis, Gastric Ulcer, Duodenal Ulcer
- Trial name
- NCT03553563
- Testing
- D961H capsule 10mg, D961H sachet 10mg
- Where
- 15 sites in Japan
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Refractory Reflux Esophagitis
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis
- Trial name
- NCT01321567
- Testing
- rabeprazole sodium
- Where
- 447 sites in Japan
- Volunteers
- 2,157 people
- Sponsor
- Eisai Co., Ltd.
Esophagitis, Reflux, Esophagitis, Peptic
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
This is a study to assess the efficacy and safety of 8 weeks of treatment with Dexlansoprazole modified release (MR)(60 mg daily and 90 mg daily) compared to Lansoprazole (30 mg daily) in healing subjects with endoscopically…
- Trial name
- NCT00251719
- Testing
- Dexlansoprazole MR, Lansoprazole
- Where
- 144 sites in United States, Australia and 14 more
- Volunteers
- 2,054 people
- Sponsor
- Takeda
Reflux Oesophagitis
Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
The objectives of this study were: To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal- and food- stimulated gastric pH in healthy volunteers.
- Trial name
- NCT01599858
- Testing
- YF476, Omeprazole
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Acute Coronary Syndrome, Myocardial Infarction
Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)
The purpose of the COGENT-1 clinical trial is to determine whether CGT-2168 (clopidogrel and omeprazole) compared to clopidogrel is safe and effective in reducing the incidence of gastrointestinal bleeding and symptomatic ulcer…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- COGENT-1 (NCT00557921)
- Testing
- CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
- Where
- 491 sites in United States, Australia and 14 more
- Volunteers
- 5,000 people
- Sponsor
- Cogentus Pharmaceuticals
Reflux Esophagitis
Reflux Esophagitis Phase III Study (Maintenance Treatment)
The primary objective of this study is to evaluate the efficacy of esomeprazole 20 mg once daily for 24 weeks on maintenance of Reflux Esophagitis in patients with healed reflux esophagitis in comparison with omeprazole 10 mg…
- Trial name
- NCT00634114
- Testing
- Esomeprazole, Omeprazole
- Where
- 44 sites in Japan
- Volunteers
- 540 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects
This study is a single-site, single-dose, non-randomized, open-label study to assess the absorption, metabolism, and excretion profile of [14C]X842 in healthy adult male subjects.
- Trial name
- NCT07107672
- Testing
- [14C]X842
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Jiangsu Sinorda Biomedicine Co., Ltd
Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis
Drug Use Surveillance of Vonoprazan for "Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"
The purpose of this survey is to evaluate the safety and effectiveness of vonoprazan tablets in patients with gastric ulcer, duodenal ulcer, and reflux esophagitis in the routine clinical setting.
- Trial name
- NCT03214952
- Testing
- Vonoprazan
- Where
- Japan
- Volunteers
- 3,183 people
- Sponsor
- Takeda
Gastroesophageal Reflux Disease (GERD)
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients
The purpose of the study is to access the effectiveness and safety of oral rabeprazole in the treatment of acid-related disorders in pediatric patients, focusing specifically on the manifestation of GERD (symptomatic and erosive…
- Trial name
- NCT00787891
- Testing
- rabeprazole
- Volunteers
- 127 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.